On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...
Moderna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...
Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...
Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
The world’s leading biotechnology company, Amgen, also recently inaugurated its GCC, which will employ 3,000 professionals.